NCT01628601

GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 392 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This is an observational study of patients diagnosed with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) who are insufficiently responsive to monotherapy and who are prescribed GANfort® (fixed combination of 0.3 mg bimatoprost and 5 mg timolol) by their physician.

Conditions

• Glaucoma, Open-Angle
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	Fixed combination 0.3 mg bimatoprost and 5 mg timolol	Patients with POAG or OHT prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol) treatment in a dose determined by the physician prior to study entry

Timeline

• Start date: 2010-05-01
• Primary completion: 2011-06-01
• Completion: 2011-06-01
• First posted: 2012-06-27
• Last updated: 2012-09-24
• Results posted: 2012-09-24

Locations

1 site across 1 country: Austria